Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2012, Article ID 164082, 4 pages
http://dx.doi.org/10.1155/2012/164082
Case Report

Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome

1Pediatric Hematology and Oncology Department, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran 15468-15514, Iran
2Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD 21218, USA

Received 22 August 2012; Accepted 15 October 2012

Academic Editors: S. Aksoy, K. Aogi, and F. A. Mauri

Copyright © 2012 Samin Alavi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. K. Pang, C. de Sousa, B. Lang, and M. G. Pike, “A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom,” European Journal of Paediatric Neurology, vol. 14, no. 2, pp. 156–161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. G. B. Aydin, M. T. Kutluk, M. Buyukpamukcu, C. Akyuz, B. Yalcin, A. Varan et al., “Neurological complications of neuroblastic tumors: experience of a single center,” Child's Nervous System, vol. 26, no. 3, pp. 359–365, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. P. Gorman, “Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome,” Current Opinion in Pediatrics, vol. 22, no. 6, pp. 745–750, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Krug, G. Schleiermacher, J. Michon et al., “Opsoclonus-myoclonus in children associated or not with neuroblastoma,” European Journal of Paediatric Neurology, vol. 14, no. 5, pp. 400–409, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. C. E. Catsman-Berrevoets, F. K. Aarsen, M. L. C. van Hemsbergen, M. M. Van Noesel, F. G. A. J. Hakvoort-Cammel, M. M. Van Den Heuvel-Eibrink et al., “Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up,” Pediatric Blood and Cancer, vol. 53, no. 6, pp. 1048–1053, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. E. de Grandis, S. Parodi, M. Conte et al., “Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome,” Neuropediatrics, vol. 40, no. 3, pp. 103–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. N. L. Antunes, Y. Khakoo, K. K. Matthay et al., “Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus,” Journal of Pediatric Hematology/Oncology, vol. 22, no. 4, pp. 315–320, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. M. R. Pranzatelli, E. D. Tate, A. L. Travelstead, and D. Longee, “Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome,” Pediatrics, vol. 115, no. 1, pp. e115–e119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. R. Pranzatelli, E. D. Tate, A. L. Travelstead et al., “Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome,” Journal of Pediatric Hematology/Oncology, vol. 28, no. 9, pp. 585–593, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. R. Pranzatelli, E. D. Tate, A. L. Travelstead, and J. A. Colliver, “Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus,” Journal of Clinical Immunology, vol. 30, no. 1, pp. 106–113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Battaglia, E. de Grandis, M. Mirabelli-Badenier et al., “Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments,” European Journal of Paediatric Neurology, vol. 16, no. 2, pp. 192–195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. J. Burke and S. L. Cohn, “Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma,” Pediatric Blood and Cancer, vol. 50, no. 3, pp. 679–680, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. J. Grillo-López, C. A. White, C. Varns et al., “Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma,” Seminars in Oncology, vol. 26, no. 5, supplement 14, pp. 66–73, 1999. View at Google Scholar · View at Scopus
  14. A. Pestronk, J. Florence, T. Miller, R. Choksi, M. T. Al-Lozi, T. D. Levine et al., “Treatment of IgM antibody associated polyneuropathies using rituximab,” Journal of Neurology Neurosurgery and Psychiatry, vol. 74, no. 4, pp. 485–489, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. J. H. Anolik, D. Campbell, R. E. Felgar et al., “The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 48, no. 2, pp. 455–459, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Quartier, B. Brethon, P. Philippet, J. Landman-Parker, F. Le Deist, and A. Fischer, “Treatment of childhood autoimmune haemolytic anaemia with rituximab,” The Lancet, vol. 358, no. 9292, pp. 1511–1513, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. B. H. Kushner, M. P. Laquaglia, M. A. Bonilla et al., “Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age,” Journal of Clinical Oncology, vol. 12, no. 12, pp. 2607–2613, 1994. View at Google Scholar · View at Scopus
  18. M. R. Pranzatelli, E. D. Tate, I. Galvan, and A. Wheeler, “A controlled pilot study of piracetam for pediatric opsoclonus-myoclonus,” Clinical Neuropharmacology, vol. 24, no. 6, pp. 352–357, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. E. D. Tate, T. J. Allison, M. R. Pranzatelli, and S. J. Verhulst, “Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome,” Journal of Pediatric Oncology Nursing, vol. 22, no. 1, pp. 8–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Ertle, W. Behnisch, N. A. al Mulla et al., “Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses,” Pediatric Blood and Cancer, vol. 50, no. 3, pp. 683–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. R. Pranzatelli, E. D. Tate, S. Shenoy, and A. L. Travelstead, “Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus,” Pediatric Blood and Cancer, vol. 58, no. 6, pp. 988–991, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. R. Pranzatelli, A. L. Travelstead, E. D. Tate, T. J. Allison, and S. J. Verhulst, “CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity,” Movement Disorders, vol. 19, no. 7, pp. 770–777, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. J. B. Chung, A. D. Wells, S. Adler, A. Jacob, L. A. Turka, and J. G. Monroe, “Incomplete activation of CD4 T cells by antigen-presenting transitional immature B cells: implications for peripheral B and T cell responsiveness,” Journal of Immunology, vol. 171, no. 4, pp. 1758–1767, 2003. View at Google Scholar · View at Scopus
  24. M. R. Pranzatelli, E. D. Tate, E. R. Hoefgen, J. A. Swan, and J. A. Colliver, “Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome,” Cytokine, vol. 44, no. 1, pp. 26–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. R. Pranzatelli, E. D. Tate, A. L. Travelstead, and S. J. Verhulst, “Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS,” Cytokine, vol. 53, no. 3, pp. 384–389, 2011. View at Publisher · View at Google Scholar · View at Scopus